Milestone! A Chinese Scientist Team Unveils a New Approach to Anti - aging and Lifespan Extension
Release time:
2025-06-19
As individuals age, the reserve of stem cells gradually depletes, leading to a decline in tissue regeneration and the ability to maintain homeostasis. This is a key characteristic of organismal aging and age - related diseases. However, a fundamental question in the field remains: Is stem cell depletion a driving factor or merely a by - product of aging? Can exogenous stem cell transplantation effectively slow down the aging process? These are the core scientific issues that urgently need to be addressed.
Meanwhile, the aging microenvironment is characterized by persistent oxidative stress, toxins, and inflammation. These negative conditions result in low implantation efficiency and short functional residence time of human stem cells in the host area. Moreover, the potential tumorigenic risk associated with transplantation has restricted the application of stem cell therapy in aging intervention.
Research Team Develops Anti - aging Engineered Cells
Recently, the research group led by Liu Guanghui from the Institute of Zoology, Chinese Academy of Sciences, in collaboration with the teams of Wang Si from Xuanwu Hospital, Capital Medical University, and Qu Jing from the Institute of Zoology, Chinese Academy of Sciences, published a significant research paper in the journal Cell. This study delved deep into the aging regulatory mechanism and used synthetic biology methods to reprogram the longevity gene pathway. As a result, engineered human anti - aging mesenchymal progenitor cells (SRC) with triple resistance to aging, stress, and malignant transformation were successfully constructed.
As early as 2011, based on the large - fragment homologous recombination platform of the third - generation high - capacity adenovirus vector (HDAdV), the research team achieved the precise targeted correction of premature - aging - causing genes in human pluripotent stem cells for the first time. This laid the theoretical foundation for the generation of engineered long - lived cells. After more than a decade of exploration, the team systematically decoded the regulatory pathways of cellular aging and established the SRC technology system. In SRC1.0, the antioxidant hub gene NRF2 was precisely edited to strengthen the intracellular endogenous antioxidant defense network. In SRC2.0, the longevity node gene FOXO3 was engineered at two sites, endowing progenitor cells with enhanced and transplantable functional characteristics.
Remarkable Anti - aging Efficacy and Promising Clinical Translation
Researchers conducted a systematic analysis of the anti - aging phenotypes of SRC2.0 and found that it has significant anti - aging activity, strong environmental adaptability, and excellent safety. In an experimental model of elderly cynomolgus monkeys, regular doses of SRC were administered. Monitoring data showed that multiple intravenous injections of SRC did not cause any adverse events, and it was confirmed that SRC transplantation has excellent safety and immunotolerance in non - human primate models.
Further evaluation revealed that SRC cell transplantation can significantly slow down the aging process of multiple organs in monkeys and restore the body's homeostasis. At the functional level, it enhances the cognitive function of elderly primates; at the tissue level, it improves degenerative changes in multiple tissues; at the cellular and molecular levels, it reduces the abnormal accumulation of senescent cells and inhibits the infiltration of inflammatory cells; at the gene expression level, it achieves a systematic rejuvenation of the aging - related gene expression network in more than half of the tissues. Mechanistic studies suggest that exosomes released by SRC play a central role in promoting cellular rejuvenation.
This research breaks through the limitations of traditional "single - disease targeted therapy." For the first time, it demonstrates that human SRC can cross species and individual differences among primates, systematically delaying the aging of multiple organs. It shows broad anti - aging efficacy and outstanding safety. As the first pre - clinical protocol for cellular anti - aging in primates that is both safe and effective, it provides a crucial reference and technical framework for future clinical trials on human aging intervention. SRC not only holds the promise of delaying physiological aging but also offers potential cell - based drugs for various age - related diseases. It is expected to shift the paradigm of aging intervention from "passive response" to "active programming," opening up a new path for actively extending human healthy lifespan.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
